ImpediMed (IPD) Stock Price, News & Analysis

Company Overview

ImpediMed Limited, a medical technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema, and deliver snapshot of fluid status and tissue composition; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1.62 million shs
• Average Volume: N/A
• Market Capitalization: A$103.31 million
• P/E Ratio: N/A
• Dividend Yield: 3.28%
• Price Target: N/A
• Consensus Rating: N/A

IPD Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of ImpediMed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ImpediMed investors own include Bardoc Gold (BDC) and Appen (APX).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Medical Devices
• Sub-Industry: N/A
• Current Symbol: ASX:IPD
• CIK: N/A
• Web: www.impedimed.com
• Phone: 61 7 3860 3700
• Fax: N/A
• Employees: 76
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -102.5
• Net Income: -A$19.79 million
• Net Margins: -191.78%
• Pretax Margin: N/A
• Return on Equity: -43.15%
• Return on Assets: -25.96%

Debt

• Debt-to-Equity Ratio: 2.81
• Current Ratio: 6.33
• Quick Ratio: 6.23

Sales & Book Value

• Annual Sales: A$10.32 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 1.60
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,020,000,000
• Free Float: N/A
• Market Cap: A$103.31 million
• Optionable: Not Optionable
• Beta: 2.86